The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study by Bonds, Denise E et al.
RESEARCH
The association between symptomatic, severe
hypoglycaemia and mortality in type 2 diabetes:
retrospectiveepidemiologicalanalysisoftheACCORDstudy
DeniseEBonds,medicalofficer,
1MichaelEMiller,professorofbiostatistics,
2RichardMBergenstal,executive
director,
3JohnBBuse,professorofmedicine,
4RobertPByington,professorofepidemiologyandprevention,
2
Jeff A Cutler, research consultant,
1 R James Dudl, diabetes clinical lead,
5 Faramarz Ismail-Beigi, professor of
medicine,
6 Angela R Kimel, research associate,
2 Byron Hoogwerf, clinical research physician,
7,8 Karen R
Horowitz, associate professor of medicine,
6 Peter J Savage, senior advisor for clinical diabetes studies,
9
ElizabethRSeaquist,professorofmedicine,
10DebraLSimmons,associateprofessorofmedicine,
11,12WilliamI
Sivitz, professor of medicine,
13 Joann M Speril-Hillen, senior clinical investigator,
14 Mary Ellen Sweeney,
associate professor of medicine
15,16
ABSTRACT
Objective To determine whether there is a link between
hypoglycaemia and mortality among participants in the
Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial.
Design Retrospective epidemiological analysis of data
from the ACCORD trial.
Setting Diabetes clinics, research clinics, and primary
care clinics.
ParticipantsPatientswereeligiblefortheACCORDstudyif
they had type 2 diabetes, a glycated haemoglobin
(haemoglobin A1C) concentration of 7.5% or more during
screening, and were aged 40-79 years with established
cardiovascular disease or 55-79 years with evidence
of subclinical disease or two additional cardiovascular
risk factors.
Intervention Intensive (haemoglobin A1C <6.0%) or
standard (haemoglobin A1C 7.0-7.9%) glucose control.
OutcomemeasuresSymptomatic,severehypoglycaemia,
manifest as either blood glucose concentration of less
than 2.8 mmol/l (<50 mg/dl) or symptoms that resolved
with treatment and that required either the assistance of
another person or medical assistance, and all cause and
cause specific mortality, including a specific assessment
for involvement of hypoglycaemia.
Results 10194 of the 10251 participants enrolled in the
ACCORD study who had at least one assessment for
hypoglycaemia during regular follow-up for vital status
were included in this analysis. Unadjusted annual
mortality among patients in the intensive glucose control
arm was 2.8% in those who had one or more episodes of
hypoglycaemia requiring any assistance compared with
1.2% for those with no episodes (53 deaths per 1924
person years and 201 deaths per 16315 person years,
respectively;adjustedhazardratio(HR)1.41,95%CI1.03
to1.93).Asimilarpatternwasseenamongparticipantsin
the standard glucose control arm (3.7% (21 deaths per
564 person years) v 1.0% (176 deaths per 17297 person
years); adjusted HR 2.30, 95% CI 1.46 to 3.65). On the
other hand, among participants with at least one
hypoglycaemic episode requiring any assistance, a non-
significantly lower risk of death was seen in those in the
intensive arm compared with those in the standard arm
(adjusted HR 0.74, 95% 0.46 to 1.23). A significantly
lower risk was observed in the intensive arm compared
with the standard arm in participants who had
experienced at least one hypoglycaemic episode
requiring medical assistance (adjusted HR 0.55, 95% CI
0.31to 0.99). Ofthe 451 deathsthat occurredin ACCORD
up to the time when the intensive treatment arm was
closed,onedeathwasadjudicatedasdefinitelyrelatedto
hypoglycaemia.
Conclusion Symptomatic, severe hypoglycaemia was
associated with an increased risk of death within each
study arm. However, among participants who
experienced at least one episode of hypoglycaemia, the
risk of death was lower in such participants in the
intensive arm than in the standard arm. Symptomatic,
severe hypoglycaemia does not appear to account for the
difference in mortality between the two study arms up to
the time when the ACCORD intensive glycaemia arm was
discontinued.
Trial registration NCT00000620.
INTRODUCTION
Reduction of blood glucose concentration among
patientswithtype2diabeteshasbeenshowntoreduce
microvascular complications.
1 Several epidemiologi-
cal studies have reported an increased risk of death
andcardiovasculardiseasewithincreasedlevelsofgly-
cated haemoglobin (haemoglobin A1C).
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Action to Control Cardiovascular Risk in Diabetes
1National Heart, Lung, and Blood
Institute, National Institutes of
Health, Bethesda, MD 20892, USA
2Division of Public Health
Sciences, Wake Forest University
Health Sciences, Winston-Salem,
NC 27157-1063, USA
3International Diabetes Center at
Park Nicollet, Minneapolis, MN
55416-2699, USA
4University of North Carolina
School of Medicine, Chapel Hill,
NC 27514, USA
5Care Management Institute,
Kaiser Permanente, Oakland, CA
94612, USA
6Case Western Reserve University,
Cleveland, OH 44106, USA
7Department of Endocrinology,
Diabetes, and Metabolism,
Cleveland Clinic, Cleveland, OH
44195, USA
8Lilly USA, Lilly Corporate Center,
Indianapolis, IN 46285, USA
9National Institute of Diabetes and
Digestive and Kidney Disease,
National Institutes of Health,
Bethesda, MD 20892, USA
10Department of Medicine,
University of Minnesota,
Minneapolis, MN 55455, USA
11University of Arkansas for
Medical Sciences, Little Rock, AR
72205, USA
12John L McClellan Memorial
Veterans Hospital, Central Arkansas
Veterans Healthcare System,
Little Rock, AR 72205, USA
13Department of Internal Medicine,
University of Iowa Health Care,
Iowa City, IA 52242, USA
14HealthPartners Research
Foundation, Minneapolis, MN
55440-1524, USA
15Emory University School of
Medicine, Atlanta, GA 30322, USA
16Atlanta Veterans Administration
Medical Center, Atlanta, GA
30033, USA
Correspondence to: DE Bonds
bondsde@nhlbi.nih.gov
Cite this as: BMJ 2009;339:b4909
doi:10.1136/bmj.b4909
BMJ | ONLINE FIRST | bmj.com page 1 of 9(ACCORD) study was initiated, however, the avail-
able evidence did not clearly support the hypothesis
that aggressive lowering of blood glucose concentra-
tion in patients with type 2 diabetes would result in
cardiovascular benefit.
5 Thus, the ACCORD trial
was designed to test the hypothesis that reducing
blood glucose concentrations to near normal levels in
adults with type 2 diabetes at high risk of a cardio-
vascular event would result in a reduction in non-fatal
and fatal cardiovascular disease.
Participants in the ACCORD study were randomly
assigned to receive therapy for intensive glycaemia
controlortherapyforstandardglycaemiacontrol.Vis-
its for the management of glycaemia medication were
every two months for participants in the intensive arm
and every four months for participants in the standard
arm. Participants also used a home glucose measure-
mentdevicetwotoeighttimesaday(intensivearm)or
less than one to three times a day (standard arm). The
Vanguard phase of the study started in 2001, and the
main trial in 2003.
In February 2008, the ACCORD intensive glycae-
mia control intervention was stopped early because of
higher mortality in this study arm: 1.42% of patients
diedeachyearcomparedwith1.14%ayearinthestan-
dard intervention arm (hazard ratio (HR) 1.22, 95%
confidence interval (CI) 1.01 to 1.46; P=0.04).
6 The
mean duration of follow-up at the time the intensive
intervention was stopped was 3.5 years. The underly-
ing cause of the increased mortality in the intensive
arm was unclear at the time that the intervention was
stopped, although several hypotheses were proposed,
including severe hypoglycaemia.
Hypoglycaemia is a major risk of intensive glucose
control.Althoughmildepisodesgenerallyarewelltol-
erated,severehypoglycaemiacancauseseriousinjury,
unconsciousness, seizures, coma, myocardial ischae-
mia, angina, residual neurological impairment, or
death. A higher rate of severe hypoglycaemia was
expected a priori in the ACCORD intensive arm par-
ticipants compared with the normal arm participants
and, as expected, was seen in the intensive arm at the
time of discontinuation of the intensive glycaemia
intervention.
6
Few studies have examined the association between
severe hypoglycaemia and mortality in patients with
type 2 diabetes. Case reports exist of patients with
documented hypoglycaemic episodes who subse-
quently had motor vehicle accidents that could be
attributedtotheirlowlevelsofbloodglucose.
7Apopu-
lation study of patients admitted to hospital for acute
myocardial infarction found that individuals with glu-
cose levels at the extreme ends of the spectrum (high
and low) had higher mortality rates at hospital admis-
sion and at both 30 days and one year after the event
than those with normal blood glucose levels. This U
shaped curve was present for individuals with and
without clinically recognised diabetes.
8
The ACCORD clinical trial offers an excellent
opportunitytoexamine the relationbetween hypogly-
caemia and mortality. The objectives of this particular
analysis were threefold: a) to determine if participants
in the ACCORD trial who experienced one or more
severe symptomatic hypoglycaemic episodes had an
increased risk of death; b) to determine whether that
risk differed by glycaemic control study arm; and c)
to establish whether the risk can explain all or any of
the excess mortality in the intensive arm compared
with the standard arm. The blinded results of the adju-
dication process for cause of death and the relation of
hypoglycaemia tomortality,asperformedbytheCen-
tralMorbidityandMortalityCommittee,arereported,
and the influence of incidental hypoglycaemia (symp-
tomatic or asymptomatic) is explored.
METHODS
The ACCORD study is a double 2×2 factorial trial
designed to test the effect of intensive glucose control
compared with standard glucose control, intensive
blood pressure control compared with standard
blood pressure control, and a lipid treatment strategy
that uses fenofibrate plus a statin compared with one
that uses a statin alone. The primary outcome is myo-
cardial infarction, stroke, or cardiovascular death.
9
The intensive glycaemia intervention was stopped
early owing to increased mortality in the glycaemia
control arm, and all participants were transitioned to
the standard glycaemia control intervention. These
results have been previously reported,
6 as has a full
description of the methodology and the rationale for
the trial.
910
Forthisanalysis,weuseddatasubmittedtothecoor-
dinating centre up until 10 December 2007, which
were used by the data and safety monitoring board to
make its recommendation to halt the intensive glycae-
mia intervention. The full ACCORD trial protocol is
available at http://www.accordtrial.org/web/public/
documents/Protocol%20All%20Chapters.pdf?
CFID=360349&CFTOKEN=40333908.
Study participants and design
Briefly, participants were eligible to enrol in the
ACCORD study if they had type 2 diabetes, a haemo-
globin A1C concentration of 7.5-11%, and were: a)
between the ages of 40 and 79 years with cardio-
vascular disease; or b) between the ages of 55 and
79 years with evidence of significant atherosclerosis,
albuminuria, left ventricular hypertrophy, or two or
more additional risk factors for cardiovascular disease
(dyslipidaemia, hypertension, current smoking, or
obesity). Exclusion criteria were a history of frequent
or recent serious hypoglycaemic events (hypo-
glycaemic coma or seizure within the past 12 months
or hypoglycaemia requiring third party assistance in
the past three months with concomitant glucose con-
centration of less than 3.3 mmol/l (60 mg/dl)), unwill-
ingness to do home glucose monitoring or inject
insulin,aBMIofmorethan45,aserumcreatininecon-
centration of more than 133 µmol/l (1.5 mg/dl)), or
other serious illness.
RESEARCH
page 2 of 9 BMJ | ONLINE FIRST | bmj.comParticipants were randomly assigned to receive inten-
sivetherapytargetingahaemoglobinA1Cconcentration
oflessthan6.0%ortoreceivestandardtherapytargeting
ah a e m o g l o b i nA 1C level of 7.0-7.9%. All participants
received instructional materials and behavioural coun-
selling regarding diabetes care and were provided with
glucose lowering medications and glucose monitoring
suppliesfromastudysupervisedformulary.Therapeutic
regimens were individualised at the discretion of inves-
tigators and participants on the basis of study group
assignment and response to therapy.
Diabetes care was provided in a variety of settings
(diabetes clinics, research clinics, and primary care
clinics) by physicians with diverse training. Any
approved glucose lowering medication not in the
study formulary could also be prescribed but was not
provided by the study.
Participants in the intensive arm of the study
attended a clinic for management of glycaemia medi-
cation every two months, whereas those in the stan-
dard arm attended a clinic every four months.
Outcomes were assessed every four months. Recom-
mended frequency of home glucose monitoring ran-
ged from two to eight times a day for participants in
the intensive arm and from less than one to three
times a day for participants in the standard arm,
depending on treatment response.
Definition of hypoglycaemia
Participants were asked at every visit if they had experi-
enced episodes of low blood sugar. Circumstances
surrounding episodes of symptomatic, severe hypo-
glycaemia were investigated further by the research
staff and information on precipitatingevents, symptoms,
and consequences were recorded. All symptomatic,
severe hypoglycaemic events were reported to the coor-
dinatingcentre,andthoseeventsrequiringmedicalassis-
tance were reported as serious adverse events.
A full description of the review and adjustment of
therapeuticgoalsinresponsetoseverehypoglycaemia
has been previously reported.
11 Briefly, all hypo-
glycaemic events reported as serious adverse events
were reviewed internally by an expert in diabetes
care and externally by an independent advisory
board.Afteraparticipanthadexperiencedthreehypo-
glycaemic events requiring medical assistance, their
haemoglobin A1C goal was altered. Review of hypo-
glycaemic events and procedures for goal alteration
were the same regardless of study arm.
Three separate definitions of hypoglycaemia were
used to evaluate possible associations between hypo-
glycaemia and mortality. Each of these approaches is
described below.
Symptomatic, severe hypoglycaemic event requiring medical
assistance (HMA)
At each visit, participants were asked if they had
experienced an episode of severe hypoglycaemia in
which they had received care at a hospital, at an emer-
gencyroom,orfrommedicalpersonnel.Symptomatic,
severe hypoglycaemia was defined as either a blood
glucose concentration of less than 2.8 mmol/l
(50 mg/dl) or symptoms that promptly resolved with
oral carbohydrate, intravenous glucose, or subcuta-
neous or intramuscular glucagon.
Symptomatic, severe hypoglycaemic event requiring any
assistance (HA)
Hypoglycaemia needing any assistance was defined as
an episode of symptomatic, severe hypoglycaemia in
which the participant reported receiving either medi-
cal care or assistance from another individual and had
either a documented blood glucose concentration of
less than 2.8 mmol/l (50 mg/dl) or recovery with car-
bohydrate treatment.
Hypoglycaemia based on a finger stick blood glucose
measurement of less than 3.9 mmol/l in self report log
At each visit, the number of blood sugar values below
3.9 mmol/l (70 mg/dl) in the previous seven days was
determined from the finger stick glucose record main-
tained by the participant or from information down-
loaded from the participant’s glucose monitoring
meter.
In this study, there are 19 fewer hypoglycaemic
eventsatthetimetheintensiveglycaemiacontrolinter-
vention was stopped than in previous reports
6 because
this paper’s analyses only include hypoglycaemic
events that occurred before an official four month
assessment for vital status within each glycaemia arm.
Study outcomes
TheprimaryoutcomefortheACCORDtrialisthefirst
episode of non-fatal myocardial infarction, non-fatal
stroke, or cardiovascular death. All events were cen-
trally adjudicated by at least two members of the
ACCORDstudymorbidityandmortalitysubcommit-
tee, who were masked to the participants’ randomisa-
tion status and their most recent haemoglobin A1C
measurement.
The primary outcome in this analysis was all cause
and cause specific mortality. All deaths were reviewed
twice. The case was initially reviewed to classify the
primary cause of death into one of the following
groups: cardiovascular death (including unexpected
and presumed cardiovascular death), fatal myocardial
infarction, fatal congestive heart failure, or other
cardiovascular cause; cancer; non-cardiovascular,
non-cancer; or unable to classify. Subsequent review
by at least two clinicians with expertise in diabetes
care determined whether hypoglycaemia was a proxi-
mate contributor to the death. The classification
scheme for involvement of hypoglycaemia in the
death had four categorical levels: unlikely; possible;
probable; and definite. Disagreements between
reviewers were resolved either by a third reviewer
(for possibledisagreements)or by the full adjudication
committee (for any case involving at least one vote of
“probable”or“definite”).Todeterminewhetherhypo-
glycaemia was involved in a death, adjudicators were
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ticipant was prescribed, details of any previously
reported episodes of severe hypoglycaemia and the
number of days these episodes occurred before the
death, and information on the number of times a
week the participant reported checking blood glucose
levels with their finger stick device. This information
was provided for all visits occurring within one year
before the death.
Statistical analysis
All statistical analyses were conducted with SAS soft-
ware, version 9.1. Baseline means and proportions
were compared between deceased participants with a
history of hypoglycaemia and those without by using
two sample Student’s t tests and chi square tests. The
proportion of participants deceased was summarised
on the basis of glycaemia intervention group and the
number of HMA and HA events before death. Crude,
annualised mortality rates within glycaemia inter-
vention groups were determined with and without
hypoglycaemic events. These rates were calculated by
dividingthenumberofdeathsbythecumulativetimeat
risk with and without a history of severe hypoglycae-
mia. Levin’sa t t r i b u t a b l er i s k ,
12 also referred to as the
aetiological fraction,
13 was calculated within the inten-
siveandstandardglycaemiagroupstoestimatethepro-
portion of deaths during follow-up that could be
attributable to HMA and HA events. This parameter
can be expressed as a function of the relative risk of
death and the prevalence of hypoglycaemia (aetiologi-
calfraction=v(RR−1)/[v(RR−1)+1],wherevisthepre-
valence of hypoglycaemia and RR is relative risk). The
asymptotic variance noted in Leung and Kupper was
used to obtain 95% confidence intervals.
14
AnalysisoftimeuntildeathwasperformedusingCox
proportional hazards regression analyses. A model for
death that included adjusting for pre-specified baseline
covariates was developed. Baseline covariates consid-
ered for inclusion in this model were: demographic
and anthropometric characteristics (age, gender, ethni-
city, education level, and BMI); medical history (smok-
ing history, use of alcohol, history of cardiovascular
disease, duration of diabetes, history of congestive
heartfailure,previousamputation,evidenceofprevious
myocardial infarction on baseline electrocardiogram,
history of peripheral neuropathy, visual acuity,
15 heart
rate, and electrocardiogram QT index
16); medication
use (any use of hypertension medications, angiotensin
converting enzyme inhibitors, beta blockers, statins,
alpha glucosidase inhibitors, metformin, sulphonylur-
eas, thiazolidinediones, meglitinides, and any insulin
(basal insulin, bolus insulin, and premixed insulin));
and laboratory and clinical measures (albumin to creati-
nineratio,haemoglobinA1Clevel,glucoselevel,systolic
blood pressure, diastolic blood pressure, low density
lipoprotein concentration, high density lipoprotein
concentration, and concentration of triglycerides). This
model also contained terms representing the glycaemia
control study arm plus terms accounting for the
following stratifying variables: assignment to the blood
pressure control trial or the lipid control trial; assign-
ment to the intensive blood pressure intervention in
the blood pressure control trial; and assignment to
receive fibrate in the lipid control trial. Variables with
P<0.15 when entered individually into a Cox model
were subsequently submitted to a stepwise procedure
to develop a final model for use when investigating
the association of symptomatic, severe hypoglycaemia
with death.
In models exploring the effect of HMA and HA
eventsondeath,atimedependentcovariaterepresent-
ing the occurrence of a hypoglycaemic event or the
number of previous events was used to estimate the
hazard ratio associated with a history of hypoglycae-
mia. Interactions between the glycaemia intervention
arm and occurrence of hypoglycaemia were explored
byenteringglycaemiainterventionarmvariablesmul-
tiplied by time dependent hypoglycaemia variables
into the model. Hazard ratios and 95% confidence
intervals from these models containing interactions
are presented by glycaemia intervention arm or epi-
sode of hypoglycaemia. Results are presented both
adjusted and unadjusted for baseline covariates.
Further exploratory analyses were performed after
creatingavariabletorepresenttheupdatedmeannum-
ber of blood sugar values below 3.9 mmol/l in the
seven days before the last clinic visit. This variable
was usedas a time dependentcovariate within propor-
tional hazards regression models to explore whether
the effects of this variable on mortality were consistent
by level of glycaemia intervention and history of
HMA. These models were adjusted for the average
number of finger stick blood glucose checks the parti-
cipant conducted in a week.
RESULTS
In total, 10251 individuals were enrolled in the
ACCORD trial (5128 in the intensive arm and 5123
in the standard arm), 460 of whom had died and were
includedinthedatasetassessedwhentheintensivegly-
caemia protocol was stopped early in January 2008.
6
The crude, annualised mortality rate was 1.14% a
year in the standard glycaemia control arm and
1.42% a year in the intensive glycaemia control arm.
Of the deceased participants, 451 had completed a
scheduled follow-up visit to ascertain if they had
experienced an episode of severe hypoglycaemia
before death. More participants in the intensive arm
than the standard arm experienced an episode of HA
(816 (15.9%) v 256 (5.0%)) or HMA (528 (10.3%) v 175
(3.4%)). A total of 703 participants experienced an
HMA at some point in the study. An additional 369
individuals reported at least one event requiring assis-
tance of another person but did not report an event
requiring medical assistance.
Theproportionofparticipantswhodiedstratifiedby
the number of previous hypoglycaemic events and by
glycaemia intervention treatment arm is shown in
table 1. Among the 451 individuals who died, 377
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On the other hand, 74 of those who died had experi-
encedatleastoneHA and51atleastoneHMA.Over-
all in the ACCORD study, mortality rates in
participants who experienced at least one HA, or the
more restrictive HMA, were higher than in partici-
pants with no history of HA or HMA (74/1072
(6.9%) v 377/9122 (4.1%) and 51/703 (7.3%) v 400/
9491(4.2%),respectively;seetable 1),withthehighest
rate seen in those participants with three events or
more (HM: 13/172 (7.6%), HMA: 9/59 (15.3%)).
When analyses stratified by study arm were per-
formed, the findings were similar in the standard arm
andthe intensivearm.Coxregressionanalysesoftime
betweenentryintothestudyanddeathidentifiedasig-
nificant interaction between the number of HMA epi-
sodes and the glycaemia control arm (P=0.0494). This
interaction indicated that the risk of death in partici-
pants with no history of HMA events was greater in
thosein the intensivearmthanin thosein the standard
arm (HR 1.25, 95% CI 1.03 to 1.52). However, the
mortality risk was lower in the intensive arm than in
the standard arm among participants with one, two,
or three or more HMA events (HR 0.63, 95% CI 0.31
to 1.28; HR 0.30, 95% CI 0.06 to 1.51; and HR 0.45,
95% CI 0.11 to 1.81, respectively; table 1). The inter-
action between the number of HA episodes and the
glycaemia control arm was also not significant
(P=0.2264).
Onthebasisoftheinformationintable 1,thepropor-
tion of deaths during follow-up that could be attributa-
ble to HA events was 5.9% (95% CI 2.8 to 12.2) in the
intensivearmand5.1%(95%CI1.6to15.2)inthestan-
dard arm. The proportion of deaths that could be attri-
butabletoHMAevents(theaetiological fraction) in the
intensive treatmentarm wasestimated tobe3.4% (95%
CI0.9to12.3),whereasthisvaluewas5.4%(95%CI2.6
to 12.3) in the standard treatment arm.
Table 2 shows the crude, annualised mortality rates,
total number of deaths per person years of follow-up,
and hazard ratios within glycaemia treatment arm by
history of symptomatic, severe hypoglycaemia. When
using previous hypoglycaemia as a “yes” or “no” indi-
cator rather than a count of previous events (as
reported earlier), there was a significant interaction
between history of HMA and the glycaemia inter-
vention arm (P=0.009), indicating that the glycaemic
control treatment had a different effect according to
whether or not the patient had a history of HMA.
The annual mortality rate among participants who
had never experienced an HMA was higher among
participants in the intensive arm than in those in the
standard arm (1.3% a year v 1.0% a year; HR 1.25,
95% CI 1.03 to 1.52). When mortality among partici-
pants who had experienced an HMA event was com-
pared,however,theannualmortalityratewaslowerin
theintensivearmthaninthestandardarm(2.8%ayear
v4.9%ayear;HR0.55,95%CI0.31to0.99),indicating
a lower relative risk of death among those in the inten-
sive arm who had experienced hypoglycaemia than in
those in the standard arm who had experienced hypo-
glycaemia.Asimilartrendwasseenwhentheintensive
andstandardarmswerecomparedamongparticipants
who had an HA (HR 0.74, 95% CI 0.45 to 1.23).
Wenextanalysedinformationfromthelogsoffinger
stick blood glucose measurements collected in the
seven days before each four month visit. We found
that there were more incidences where blood glucose
was less than 3.9 mmol/l in the intensive treatment
group than in the standard treatment group (intensive
1.21±SD1.84 and standard 0.32±SD0.91; P<0.001).
Therewasnosignificantrelationbetweenselfreported
Table 1 |Mortality, proportion deceased, and episodes of hypoglycaemia among all participants and by study arm
Deaths (deceased/n (%)) Hazard ratio: intensive versus
standard glycaemia control
(results from Cox models with
number of hypoglycaemic events
as a time dependent covariate) All participants Standard group Intensive group
All participants 451/10 194 (4.40) 197/5088 (3.87) 254/5106 (4.97)
Hypoglycaemic events requiring any assistance, medical or non-medical (HA) Test of interaction: number of
hypoglycaemic events versus
glycaemia control arm (P=0.2264)
Participants with no events 377/9122 (4.13) 176/4832 (3.64) 201/4090 (4.69) 1.21 (0.99 to 1.48)
Participants with at least one event 74/1072 (6.90) 21/256 (8.20) 53/816 (6.49) —
One event 47/704 (6.68) 13/176 (7.39) 34/528 (6.44) 0.84 (0.44 to 1.60)
Two events 14/196 (7.14) 4/51 (7.84) 10/145 (6.90) 0.71 (0.22 to 2.25)
Three events or more 13/172 (7.56) 4/29 (13.79) 9/143 (6.29) 0.44 (0.14 to 1.43)
Hypoglycaemic events requiring medical assistance (HMA) Test of interaction: number of
hypoglycaemic events versus
glycaemia control arm (P=0.0494)
Participants with no events 400/9491 (4.21) 180/4913 (3.66) 220/4578 (4.81) 1.25 (1.03 to 1.52)
Participants with at least one event 51/703 (7.25) 17/175 (9.71) 34/528 (6.43) —
One event 36/529 (6.81) 11/132 (8.33) 25/397 (6.30) 0.63 (0.31 to 1.28)
Two events 6/115 (5.22) 3/33 (9.09) 3/82 (3.66) 0.30 (0.06 to 1.51)
Three events or more 9/59 (15.25) 3/10 (30.00) 6/49 (12.24) 0.45 (0.11 to 1.81)
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except among those participants who reported a his-
tory of HMA. Within this subgroup, the association
betweenselfreportedlowbloodglucoseconcentration
and risk of death was characterised by a lower risk of
death in participants who reported a larger number of
blood glucose measurements below 3.9 mmol/l (HR
0.68, 95% CI 0.36 to 1.24). In participants with no his-
tory of HMA, however, there was no relation between
self reported blood glucose concentration and risk of
death (HR 0.97, 95% CI 0.85 to 0.96; P against history
of HMA=0.0497). The relation between the risk of
death and finger stick blood glucose concentration of
lessthan3.9mmol/ldidnotdifferaccordingtoglycae-
mia control arm (P=0.2828).
Hypoglycaemia was judged to be involved in 431 of
451deathswhereenoughinformationwasavailableto
make this decision. Overall, hypoglycaemia was not
judged to have had a role in 389 (90.3%) of the 431
deaths with sufficient information to adjudicate for
hypoglycaemia. In 38 (8.8%) of the deaths, hypogly-
caemia was deemed to have had a possible role,
whereas it was felt to have a probable role in three
(0.7%) deaths. Hypoglycaemia was felt to have had a
definiteroleinthedeathofoneparticipantintheinten-
sive treatmentarm.Thesenumbersdid not varymuch
by studyarm,with hypoglycaemia thoughttopossibly
be involved in 25 (10.2%) deaths and probably be
involved in one (0.41%) death in the intensive arm,
whereas 13 (7.0%) and two (1.1%) of the deaths in par-
ticipants in the standard arm were adjudicated as pos-
siblyrelatedtohypoglycaemiaandprobablyinvolved,
respectively.
The time between the last reported episode of HA
and death was also examined. Overall, of the 74 parti-
cipants who reported any HA during the study and
died,six(8.1%)diedwithin30daysoftheevent.Asimi-
lar proportionof participants in the intensive treatment
arm (n=3 (5.7%))and inthe standardarm (n=3( 1 4 . 3 % ) )
died within 30 days of their last reported HA episode.
DISCUSSION
In this detailed analysis of participants in the
ACCORDglycaemiatrialuptothetimewhenthegly-
caemia intensive intervention was discontinued, both
participants in the intensive arm and those in the stan-
dard arm who had experienced symptomatic, severe
hypoglycaemia were at greater risk of death than
those who had not experienced any episodes of hypo-
glycaemia. Among all participants who experienced
an episode of symptomatic, severe hypoglycaemia,
however, those in the intensive arm had a lower risk
of death than those in the standard arm. Few partici-
pants died within 30 days of their most recent HA or
HMA, and only one such death was judged to be
related to hypoglycaemia. Little evidence was found
that linked either HA or HMA as measured and
recorded in the study to the increased number of
deaths among participants in the intensive arm of the
ACCORD trial.
Potential explanations for the findings
The mechanism underlying the increased mortality
among patients with severe hypoglycaemia has yet to
be elucidated. A potential possibility, however, is that
cardiac ischaemia or fatal arrhythmia during recog-
nised or unrecognised episodes of hypoglycaemia is
responsible, particularly in the setting of cardiac
autonomic neuropathy.
17 In a detailed study using
simultaneouscontinuousglucosemonitoringandelec-
trocardiogram monitoring among 19 patients with
type 2 diabetes and coronary artery disease who were
being treated with insulin, 10 episodes of angina and
four episodes of cardiac ischaemia were seen in the 26
recorded episodes of symptomatic hypoglycaemia. In
addition, two occasions of ischaemia were seen in 28
episodes of asymptomatic hypoglycaemia.
18 Change
in QT interval and QT dispersion have been seen dur-
ing controlled episodes of hypoglycaemia in other
studies.
1920
Those participants who experienced a severe hypo-
glycaemic event—both in the intensive treatment arm
Table 2 |Crude, annualised mortality rates and hazard ratios within treatment groups by occurrence of hypoglycaemia
Mortality rate (n=451 deaths) Hazard ratio for no previous events v at
least oneevent,stratifiedby glycaemia
arm* (HR (95% CI)) No previous events At least one previous event
Hypoglycaemic events requiring any assistance, medical or non-medical (HA)† †
Intensive 1.2% a year
(201 deaths/16 315 person years)
2.8% a year
(53 deaths/1924 person years)
Unadj: 1.79 (1.32 to 2.44)
Adj: 1.41 (1.03 to 1.93)
Standard 1.0% a year
(176 deaths/17 297 person years)
3.7% a year
(21 deaths/564 person years)
Unadj: 2.93 (1.86 to 4.63)
Adj: 2.30 (1.46 to 3.65)
Hypoglycaemic events requiring medical assistance (HMA)‡ ‡
Intensive 1.3% a year
(220 deaths/17 031 person years)
2.8% a year
(34 deaths/1208 person years)
Unadj: 1.72 (1.19 to 2.47)
Adj: 1.28 (0.88 to 1.85)
Standard 1.0% a year
(180 deaths/17 516 person years)
4.9% a year
(17 deaths/345 person years)
Unadj: 3.88 (2.35 to 6.40)
Adj: 2.87 (1.73 to 4.76)
*Adjusted hazard ratios are adjusted for the following baseline covariates: age, gender, smoking status, history of cardiovascular disease, history of
heart failure, peripheral neuropathy, albumin to creatinine ratio, heart rate, QT score (from electrocardiology), visual acuity score, statin use,
sulfonylurea use, glycaemia intervention, enrolled in lipid v blood pressure trial, intensive blood pressure control group, and fibrate group.
†P=0.076 for interaction between history of hypoglycaemia requiring any assistance and glycaemia intervention.
‡P=0.009 for interaction between history of hypoglycaemia requiring medical assistance and glycaemia intervention.
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death. However, a higher rate of hypoglycaemia was
seenintheintensivetreatmentarmthaninthestandard
treatmentarm,leadingtospeculationthatthisincrease
alone (with the increased risk of death among those
with hypoglycaemia) could account for the high mor-
tality in the intensive treatment group. Calculation of
the aetiological fraction is one way to determine how
many deaths are caused by a particular risk factor.
Using the aetiological fractions from the results sec-
tion, the potential number of deaths in the intensive
treatment arm caused by HMA is nine (aetiological
fraction × number of deaths in arm), compared with
11inthestandardtreatmentarm.ForHA,thepotential
number of deaths is 15 in the intensive treatment arm
and 10 in the standard treatment arm; thus, five of the
57 excess deaths in the intensive arm could be attribu-
ted to the excess HA experienced by this arm. These
numbers demonstrate that hypoglycaemia as mea-
sured in the ACCORD study cannot account for
much of the difference in mortality seen between
study arms. Further supporting this statement is the
reduced risk of death among participants in the inten-
sive treatment arm when stratified by history of symp-
tomatic, severe hypoglycaemic events.
The protocolrequiredan identicalresponsebystudy
stafftoparticipantswhoreportedanepisodeofsympto-
matic, severe hypoglycaemia. However, it may be that
the more frequent visit schedule and, therefore, higher
exposuretostudystaffintheintensiveinterventionarm
increased participants’ knowledge of the prevention
and appropriate treatment of severe hypoglycaemia,
so that participants in the intensive treatment arm
were better prepared to respond to their symptoms
than were those in the standard treatment arm.
By protocol, participants who experienced three or
more HMA events had their haemoglobin A1C goal
relaxed. More participants in the intensive treatment
arm than in the standard treatment arm experienced
threeormoreHMAeventsandhadtheirhaemoglobin
A1C goal relaxed, which may have altered their mor-
tality risk. It is also possible that the high frequency of
episodes of mild hypoglycaemiaexperienced by parti-
cipantsinthe intensivetreatmentarmprovided“train-
ing” in management techniques that could then be
applied to manage the more severe episodes that later
occurred, resulting in reduced rate of mortality in this
arm. Similarly, frequent, mild hypoglycaemia such as
that experienced by participants in the intensive gly-
caemia control arm may have preconditioned the
myocardium, similar to the process seen experimen-
tally in the brain,
21 and provided protection against
the effects of severe hypoglycaemia.
Finally, by protocol the participants in the standard
treatment arm would generally have had their glucose
lowering therapy attenuated when they reported a fin-
ger stick blood glucose measurement of less than
3.9 mmol/l. Thus, symptomatic, severe hypoglycae-
mia may have been a potent marker of underlying ill-
ness or frailty in the standard treatment arm, whereas
in the intensive treatment arm severe hypoglycaemia,
in addition to any risk related to glycaemic instability,
wasinsteadlikelytobetheresultofexcessivehypogly-
caemic treatment relative to glycaemic level, because
the limits of tolerance to mild hypoglycaemia was
pushed by protocol. The ACCORD study dataset
does not contain adequate information to explore
either of these hypotheses.
Comparison with other studies
Inthisstudy,theriskofdeathwasfoundtobehigherin
participants who had experienced at least one episode
of symptomatic, severe hypoglycaemia than in those
thatdidnotreportanevent,althoughnotemporalrela-
tion was found. The VA diabetes trial reported similar
findings,
22 as have other studies.
Svensson et al examined over 700 patients with dia-
betes admitted for unstable angina or a non-Q wave
myocardial infarction and found that those who
experienced at least one episode of hypoglycaemia
(blood glucose <3.06 mmol/l (55 mg/dl)) during hos-
pital admission had a higher two year mortality than
thosewhodidnotexperienceanyhypoglycaemia(HR
1.93, 95% CI 1.18 to 3.17).
23 A case-control study of
patients with and without diabetes in an intensive
care unit found that hypoglycaemia was an indepen-
dent risk factor for mortality (relative risk of 2.28).
24
Two randomised controlled trials conducted in criti-
cally ill patients in the intensive care unit setting also
identified severe hypoglycaemia as an independent
risk factor for mortality.
2526 It should be noted, how-
ever, that only a small fraction of the deaths reported
in the above studies were directly linked to sympto-
matic, severe hypoglycaemia. The reduced risk of
death in the intensive treatment arm is not explained
by previous studies.
These studies and our findings raise the possibility
that although a discrete hypoglycaemic episode may
not be an immediate contributor to death, susceptibil-
ity to hypoglycaemia may predict an increased risk of
death. This could also explain why a greater hazard
ratiofordeathwasseenamongparticipantsinthestan-
dardtreatmentarminwhomhypoglycaemia occurred
despite a high baseline and goal haemoglobin A1C
level. In such patients, some hypoglycaemia would
occurbecauseofaninherentinstabilityofglucosecon-
trol in the patient, whereas other episodes would be a
direct result of the treatment regimen.
Study strengths and limitations
Although this study has many strengths—including a
large number of participants, detailed information on
bothhypoglycaemiaanddeath,andtheuseofablinded
adjudication process to determine both the immediate
cause of death and the involvement of hypoglycaemia
in a death—it does also have limitations.
Continuous monitoring of the participants’ glucose
concentrations was not routinely used during the
study;instead,glucosevaluescollectedbyparticipants
in their home environment were used to assist in med-
ication adjustment. It is, therefore, possible that there
RESEARCH
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hypoglycaemia proximal to the death that could have
contributed to increased mortality in the intensive
group. There were on average more episodes of
blood glucose concentration below 3.9 mmol/l in the
seven days before a clinic visit in the intensive group;
however,therewasonlyasignificant,negativerelation
between these low blood glucose levels and mortality
in participants who had previously had an HMA,
regardless of treatment group. In participants without
a history of HMA, the risk of death was not lower in
those who reported a high number of blood glucose
values of less than 3.9 mmol/l. Variation on the basis
of low self reported blood glucose levels could be
skewed by adherent patients, who are often found to
be at lower mortality risk, but we did attempt to
accountforthischaracteristicbyadjustingforthenum-
ber of times the finger stick tests were performed.
Before March 2003, clinic sites were not required to
documentthebloodglucoseleveloftheparticipantdur-
ing an HMA. Thus we do not have information on
blood glucose level for 15% of the episodes used in the
analyses in this paper. Exclusion of events without this
documentation does not qualitatively change the con-
clusions (data not shown). Except for some patients
admitted to hospital, blood glucose concentration at
the time of death was not measured, making it difficult
to exclude asymptomatic or unrecognised hypoglycae-
mia as a proximate contributing factor to death.
Therandomisedcomparisonwasoftwostrategiesof
glycaemic therapy to attain a haemoglobin A1C goal.
The protocol provided for differential monitoring of
glucose, medication selection and titration, and toler-
ance for mild hypoglycaemia by the study clinicians;
these factors could obscure the underlying cause of
severe hypoglycaemia in this study. It is also difficult
to assess the contribution of a specific drug or drug
combination, for the same reasons.
Finally,patientswitharecenthistoryorfrequentepi-
sodes of HMA at the time of recruitment were
excluded from the ACCORD trial. This approach
may have resulted in somewhat lower estimates of
absolute mortality risk owing to the relation between
hypoglycaemia and mortality, but should not have
affected the relative difference between the intensive
treatment and standard treatment arms.
Conclusions
Insummary,althoughthemajorityofthe deathsinthe
ACCORD trial at the time of the closure of the inten-
sive treatment arm occurred among participants who
had not reported any episodes of severe hypoglycae-
mia, an increased relative risk of death was found
among those who had experienced at least one symp-
tomatic, severe hypoglycaemic episode. No temporal
relation was seen between hypoglycaemia and death,
and only one death was adjudicated as definitely
related to hypoglycaemia.
Among participants who experienced an episode of
severe hypoglycaemia, the relative risk of death was
lower in those in the intensive glycaemia treatment
arm than in those in the standard treatment arm.
Althoughhypoglycaemiacannotbeexcludedasapos-
siblecontributortodeathinsomeofthefatalcases,the
increased relative risk of mortality observed in the
intensive treatment group in the ACCORD trial can-
not be explained by severe hypoglycaemia as it was
measured in the study. Susceptibility to severe hypo-
glycaemiamaybeamarkerforanunderlyingdisorder
that increases the risk for death in patients with dia-
betes, even when glycaemia is controlled according
to current guidelines.
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